|
1
|
Ferlay J, Soerjomataram I, Ervik M,
Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and
Bray F: GLOBOCAN 2012v1.0, Cancer incidence and mortality
worldwide: IARC CancerBase No. 11 [internet]. International Agency
for Research on Cancer; Lyon: 2013, [cited 2014 Apr 25]. Available
from: http://globocan.iarc.fr.
|
|
2
|
Carneiro F: Stomach cancer. World Cancer
Report 2014. Steward B and Wild CP: International Agency for
Research on Cancer; Lyon: pp. 383–391. 2014
|
|
3
|
Koufuji K, Takeda J, Toyonaga A, Yoshihara
S, Tanaka Y, Ohta J, Aoyagi K, Yano S, Kodama I and Shirouzu K:
Early gastric cancer and lymph node metastasis. Kurume Med J.
44:157–164. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chang CH, Hsiao CF, Yeh YM, Chang GC, Tsai
YH, Chen YM, Huang MS, Chen HL, Li YJ, Yang PC, et al: Circulating
interleukin-6 level is a prognostic marker for survival in advanced
nonsmall cell lung cancer patients treated with chemotherapy. Int J
Cancer. 132:1977–1985. 2013. View Article : Google Scholar
|
|
5
|
Yanaihara N, Anglesio MS, Ochiai K, Hirata
Y, Saito M, Nagata C, Iida Y, Takakura S, Yamada K, Tanaka T, et
al: Cytokine gene expression signature in ovarian clear cell
carcinoma. Int J Oncol. 41:1094–1100. 2012.PubMed/NCBI
|
|
6
|
Ravishankaran P and Karunanithi R:
Clinical significance of preoperative serum interleukin-6 and
C-reactive protein level in breast cancer patients. World J Surg
Oncol. 9:182011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Trikha M, Corringham R, Klein B and Rossi
JF: Targeted anti-interleukin-6 monoclonal antibody therapy for
cancer: a review of the rationale and clinical evidence. Clin
Cancer Res. 9:4653–4665. 2003.PubMed/NCBI
|
|
8
|
Jones SA, Horiuchi S, Topley N, Yamamoto N
and Fuller GM: The soluble interleukin 6 receptor: mechanisms of
production and implications in disease. FASEB J. 15:43–58. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Grivennikov S and Karin M: Autocrine IL-6
signaling: A key event in tumorigenesis? Cancer Cell. 13:7–9. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Heinrich PC, Behrmann I, Haan S, Hermanns
HM, Müller-Newen G and Schaper F: Principles of interleukin
(IL)-6-type cytokine signalling and its regulation. Biochem J.
374:1–20. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ara T and Declerck YA: Interleukin-6 in
bone metastasis and cancer progression. Eur J Cancer. 46:1223–1231.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xie G, Yao Q, Liu Y, Du S, Liu A, Guo Z,
Sun A, Ruan J, Chen L, Ye C, et al: IL-6-induced
epithelial-mesenchymal transition promotes the generation of breast
cancer stem-like cells analogous to mammosphere cultures. Int J
Oncol. 40:1171–1179. 2012.
|
|
13
|
Yi H, Cho HJ, Cho SM, Jo K, Park JA, Kim
NH, Amidon GL, Kim JS and Shin HC: Blockade of interleukin-6
receptor suppresses the proliferation of H460 lung cancer stem
cells. Int J Oncol. 41:310–316. 2012.PubMed/NCBI
|
|
14
|
Liao WC, Lin JT, Wu CY, Huang SP, Lin MT,
Wu AS, Huang YJ and Wu MS: Serum interleukin-6 level but not
genotype predicts survival after resection in stages II and III
gastric carcinoma. Clin Cancer Res. 14:428–434. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lin MT, Lin BR, Chang CC, Chu CY, Su HJ,
Chen ST, Jeng YM and Kuo ML: IL-6 induces AGS gastric cancer cell
invasion via activation of the c-Src/RhoA/ROCK signaling pathway.
Int J Cancer. 120:2600–2608. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Judd LM, Menheniott TR, Ling H, Jackson
CB, Howlett M, Kalantzis A, Priebe W and Giraud AS: Inhibition of
the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and
in vivo. PLoS One. 9:e959932014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hirano T, Taga T, Nakano N, Yasukawa K,
Kashiwamura S, Shimizu K, Nakajima K, Pyun KH and Kishimoto T:
Purification to homogeneity and characterization of human B-cell
differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci USA.
82:5490–5494. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Grossman RM, Krueger J, Yourish D,
Granelli-Piperno A, Murphy DP, May LT, Kupper TS, Sehgal PB and
Gottlieb AB: Interleukin 6 is expressed in high levels in psoriatic
skin and stimulates proliferation of cultured human keratinocytes.
Proc Natl Acad Sci USA. 86:6367–6371. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kishimoto T: The biology of interleukin-6.
Blood. 74:1–10. 1989.PubMed/NCBI
|
|
20
|
Williams N, De Giorgio T, Banu N, Withy R,
Hirano T and Kishimoto T: Recombinant interleukin 6 stimulates
immature murine megakaryocytes. Exp Hematol. 18:69–72.
1990.PubMed/NCBI
|
|
21
|
Hirano T, Matsuda T, Turner M, Miyasaka N,
Buchan G, Tang B, Sato K, Shimizu M, Maini R, Feldmann M, et al:
Excessive production of interleukin 6/B cell stimulatory factor-2
in rheumatoid arthritis. Eur J Immunol. 18:1797–1801. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Matsuo K, Oka M, Murase K, Soda H, Isomoto
H, Takeshima F, Mizuta Y, Murata I and Kohno S: Expression of
interleukin 6 and its receptor in human gastric and colorectal
cancers. J Int Med Res. 31:69–75. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ataie-Kachoie P, Pourgholami MH and Morris
DL: Inhibition of the IL-6 signaling pathway: A strategy to combat
chronic inflammatory diseases and cancer. Cytokine Growth Factor
Rev. 24:163–173. 2013. View Article : Google Scholar
|
|
25
|
Hodge DR, Hurt EM and Farrar WL: The role
of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer.
41:2502–2512. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tchirkov A, Khalil T, Chautard E, Mokhtari
K, Véronèse L, Irthum B, Vago P, Kémény JL and Verrelle P:
Interleukin-6 gene amplification and shortened survival in
glioblastoma patients. Br J Cancer. 96:474–476. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gao SP, Mark KG, Leslie K, Pao W, Motoi N,
Gerald WL, Travis WD, Bornmann W, Veach D, Clarkson B, et al:
Mutations in the EGFR kinase domain mediate STAT3 activation via
IL-6 production in human lung adenocarcinomas. J Clin Invest.
117:3846–3856. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kudo M, Jono H, Shinriki S, Yano S,
Nakamura H, Makino K, Hide T, Muta D, Ueda M, Ota K, et al:
Antitumor effect of humanized anti-interleukin-6 receptor antibody
(tocilizumab) on glioma cell proliferation. Laboratory
investigation. J Neurosurg. 111:219–225. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shinriki S, Jono H, Ota K, Ueda M, Kudo M,
Ota T, Oike Y, Endo M, Ibusuki M, Hiraki A, et al: Humanized
anti-interleukin-6 receptor antibody suppresses tumor angiogenesis
and in vivo growth of human oral squamous cell carcinoma. Clin
Cancer Res. 15:5426–5434. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang SP, Wu MS, Wang HP, Yang CS, Kuo ML
and Lin JT: Correlation between serum levels of interleukin-6 and
vascular endothelial growth factor in gastric carcinoma. J
Gastroenterol Hepatol. 17:1165–1169. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jinno T, Kawano S, Maruse Y, Matsubara R,
Goto Y, Sakamoto T, Hashiguchi Y, Kaneko N, Tanaka H, Kitamura R,
et al: Increased expression of interleukin-6 predicts poor response
to chemoradiotherapy and unfavorable prognosis in oral squamous
cell carcinoma. Oncol Rep. 33:2161–2168. 2015.PubMed/NCBI
|
|
32
|
Jüttner S, Wissmann C, Jöns T, Vieth M,
Hertel J, Gretschel S, Schlag PM, Kemmner W and Höcker M: Vascular
endothelial growth factor-D and its receptor VEGFR-3: Two novel
independent prognostic markers in gastric adenocarcinoma. J Clin
Oncol. 24:228–240. 2006. View Article : Google Scholar
|
|
33
|
Mandriota SJ, Jussila L, Jeltsch M,
Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R,
Jackson DG, et al: Vascular endothelial growth factor-C-mediated
lymphangiogenesis promotes tumour metastasis. EMBO J. 20:672–682.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen Y, Jiang L, She F, Tang N, Wang X, Li
X, Han S and Zhu J: Vascular endothelial growth factor-C promotes
the growth and invasion of gallbladder cancer via an autocrine
mechanism. Mol Cell Biochem. 345:77–89. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Du Q, Jiang L, Wang X, Wang M, She F and
Chen Y: Tumor necrosis factor-α promotes the lymphangiogenesis of
gallbladder carcinoma through nuclear factor-κB-mediated
upregulation of vascular endothelial growth factor-C. Cancer Sci.
105:1261–1271. 2014. View Article : Google Scholar : PubMed/NCBI
|
